An in vivo base editing approach targeting the PRNP gene led to a 52% increase in the lifespan of mouse models inoculated with the most common sporadic and genetic types of human pathogenic prion ...

Canaccord said Science Group has an impressive and consistent track record of delivering a combination of organic and disciplined inorganic growth with minimal shareholder dilution. "This track ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...

How much is Canaccord Genuity Group Inc stock worth? Invest with precise valuations. Get Report.

Canaccord downgraded Inari Medical (NARI) to Hold from Buy with a price target of $80, up from $74, after Stryker (SYK) entered into a definitive agreement to acquire Inari in cash for $80 per ...

Canaccord analyst George Gianarikas raised the firm’s price target on Tesla (TSLA) to $404 from $298 and keeps a Buy rating on the shares. The firm says that despite Tesla’s weaker than ...

Canaccord Genuity raised its price target on Tesla (TSLA) to $404 per share from $298, citing optimism over the company’s growth, including in its energy business and possible robotics venture.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

While the company said it does not expect to see any ‘significant impact’ from the suspension, Canaccord Genuity disagreed, saying that Inkai is estimated to produce ~15% of the country’s uranium ...

Canaccord assumed coverage of the shares with a buy rating and a 60 euro ($62) price target. The stock was trading 2.4% higher at 45.65 euros at publication time. Companies like Northern Data are ...